13 results about "Soft tissue sarcoma" patented technology

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The application provides a preparation method and application of a bone and soft tissue sarcoma organoid. A bone and soft tissue sarcoma tissue sample is placed in a modified organoid culture medium and placed in a CO2 incubator for culture at 37 DEG C. Half of the medium is replaced every two days, and a bone and soft tissue sarcoma organoid can be obtained within two weeks. The method is simple to operate, significantly improves the survival rate and quantity of organoids, and shortens the culture time of organoids. Eight different subtypes of bone and soft tissue sarcoma organoids can be obtained by using the method. The bone and soft tissue sarcoma organoids obtained by the application can be passaged and stored at low temperature, retain all cell types of the original tumor tissue block, more truly simulate the tumor microenvironment, and provide more clinically consistent drug sensitivity test results. The bone and soft tissue sarcoma organoids obtained by the application can be used for personalized CAR-T treatment evaluation, drug sensitivity detection of chemotherapeutic drugs and targeted drugs, and preparation of personalized tumor vaccines.

The present invention relates to pharmaceutical compositions and methods for the treatment of carcinomas and sarcomas. In particular, the invention provides a pharmaceutical composition comprising a peptide or pharmaceutically acceptable salt thereof for use in treating a carcinoma or a sarcoma in a human subject, wherein the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1 and a cell penetrating peptide and wherein the pharmaceutical composition is systemically administered to the subject weekly to provide a dose of the peptide of about 15-65 mg / m2 body surface area (BSA) per week, calculated as the free form of the peptide.

The application relates to a preoperative risk scoring method for limb and trunk soft tissue sarcoma, which comprises the following steps: obtaining standardized MRI features of a patient, and classifying the standardized MRI features; and inputting the classification results of the standardized MRI features into a scoring model to obtain a preoperative risk score of the patient. The application can accurately evaluate the risk of limb and trunk soft tissue sarcoma non-invasively before operation by converting complex image information into a simple and understandable risk score through unified MRI feature definition and objective weight allocation, so as to provide a precise solution for preoperative planning and postoperative management of the patient.

The invention provides a dendritic cell vaccine for treating bone and soft tissue sarcoma as well as a preparation method and application of the dendritic cell vaccine. The dendritic cell vaccine comprises mature dendritic cells obtained by co-culturing sarcoma cell lysate and immature dendritic cells. The lysates of seven sarcoma cells are used as dendritic cell vaccine antigens, the problem that an existing DC vaccine is single in loaded antigen is solved, antigen presentation and T cell activation are enhanced, wide immune response is excited, immune escape is reduced, and the dendritic cell vaccine is not limited by the type of MHC of a patient, is high in universality and can benefit more patients.

This application relates, in certain embodiments, to a method and composition for treating soft tissue sarcomas (STS, e.g., spindle cell sarcoma, solitary fibrous tumor, or leiomyosarcoma) using a composition comprising nanoparticles containing an mTOR inhibitor (e.g., limus drugs, e.g., sirolimus or its derivatives) and albumin in combination with a multityrosine kinase inhibitor (e.g., pazopanib).

GD2-specific chimeric antigen receptor effector cells for the treatment of solid tumors, which can be combined with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor. ------ The present invention relates to GD2-specific chimeric antigen receptor (GD2.CAR) effector cells for the treatment of both solid tumors, particularly extracranial GD2+ tumors (such as soft tissue sarcomas and osteosarcomas, neuroblastomas, melanomas, lung cancers, bladder cancers, and retinoblastomas) and brain tumors. Furthermore, the present invention also relates to the use of GD2.CAR gene-modified effector cells in combination with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor in the treatment of solid tumors.

The present disclosure provides methods of treatment comprising anti-EDB antibodies and antibody-drug conjugates. The present disclosure further provides methods of treating EDB+ FN-expressing disorders, such as cancer. In some aspects, the method comprises administration of an anti-EDB+FN ADC to a patient having cancer, such as, for example, non-small cell lung cancer (NSCLC), breast cancer, head and neck cancer, ovarian cancer, thyroid cancer, pancreatic cancer, soft tissue sarcoma, chordoma, hepatocellular carcinoma, kidney cancer, cervical cancer, and endometrial cancer.

Disclosed in the present application is the use of a compound of formula I in the preparation of a drug for treating the following tumors, which are selected from gastric cancer, esophageal cancer, cholangiocarcinoma, nasopharyngeal cancer, soft tissue sarcoma, prostate cancer, liver cancer, non-small cell lung cancer, breast cancer, glioma, leukemia, ovarian cancer, cervical cancer, endometrial carcinoma, primary brain tumors, brain metastatic tumors, pancreatic cancer and angiosarcoma. Further disclosed is the use of the compound in combination with other anti-tumor drugs in the treatment of the above-mentioned cancers.

The present invention relates to pharmaceutical compositions and methods for the treatment of carcinomas and sarcomas. In particular, the invention provides a pharmaceutical composition comprising a peptide or pharmaceutically acceptable salt thereof for use in treating a carcinoma or a sarcoma in a human subject, wherein the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1 and a cell penetrating peptide and wherein the pharmaceutical composition is systemically administered to the subject weekly to provide a dose of the peptide of about 15-65 mg / m2 body surface area (BSA) per week, calculated as the free form of the peptide.

The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile and pharmaceutically acceptable salts and solvates thereof, that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and / or soft tissue sarcomas.

To provide use of a Mitoxantrone Hydrochloride liposome in the manufacture of a medicament for treating bone and soft tissue sarcomas.SOLUTION: Use of a Mitoxantrone Hydrochloride liposome in the manufacture of a medicament for the treatment of metastatic or locally advanced bone and soft tissue sarcomas that have failed at least first line therapy is provided.SELECTED DRAWING: None